23 results
8-K
EX-10.1
ADPT
Adaptive Biotechnologies Corp
12 Sep 22
Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million
8:45am
) any Product In-License or (f) any other investment that are or would be classified as investments on a balance sheet of such Person prepared
424B5
2e1sar fh
16 Jul 20
Prospectus supplement for primary offering
4:26pm
424B5
cgerjai56ik0kyttwx9y
14 Jul 20
Prospectus supplement for primary offering
5:01pm
10-K
bz33077cmvtd snlnhh
26 Feb 20
Annual report
4:53pm
424B4
vvwwujg q4
24 Jan 20
Prospectus supplement with pricing info
4:49pm
DRS
8jbmhdez jpf
9 Jan 20
Draft registration statement
12:00am
10-Q
nqq67 7dhrf5ctude7
13 Aug 19
Quarterly report
4:36pm
424B4
s9w4v
27 Jun 19
Prospectus supplement with pricing info
5:24pm
S-1
gq1tex5msyq6dopqiqkl
30 May 19
IPO registration
5:20pm
CORRESP
2ovll
30 May 19
Correspondence with SEC
12:00am
UPLOAD
t62d04w
23 May 19
Letter from SEC
12:00am
DRS/A
vm0x7prom5q0 x1edp
8 May 19
Draft registration statement (amended)
12:00am